Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 77

Similar articles for PubMed (Select 19657108)

1.

International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy.

Cardoso F, Bedard PL, Winer EP, Pagani O, Senkus-Konefka E, Fallowfield LJ, Kyriakides S, Costa A, Cufer T, Albain KS; ESO-MBC Task Force.

J Natl Cancer Inst. 2009 Sep 2;101(17):1174-81. doi: 10.1093/jnci/djp235. Epub 2009 Aug 5. Review.

2.

Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational?

Zhang J, Gu SY, Gan Y, Wang ZH, Wang BY, Guo HY, Wang JL, Wang LP, Zhao XM, Hu XC.

Cancer Chemother Pharmacol. 2013 Jan;71(1):103-13. doi: 10.1007/s00280-012-1983-y. Epub 2012 Oct 2.

PMID:
23053266
3.

International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?

Pagani O, Senkus E, Wood W, Colleoni M, Cufer T, Kyriakides S, Costa A, Winer EP, Cardoso F; ESO-MBC Task Force.

J Natl Cancer Inst. 2010 Apr 7;102(7):456-63. doi: 10.1093/jnci/djq029. Epub 2010 Mar 10. Review.

4.

Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.

Jones A, O'Brien M, Sommer H, Nowara E, Welt A, Pienkowski T, Rolski J, Pham ML, Perraud K, Trillet-Lenoir V.

Cancer Chemother Pharmacol. 2010 Mar;65(4):755-63. doi: 10.1007/s00280-009-1081-y. Epub 2009 Aug 9.

PMID:
19669644
5.

Re: International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy.

Chlebowski RT.

J Natl Cancer Inst. 2010 Jan 20;102(2):137. doi: 10.1093/jnci/djp465. Epub 2009 Dec 17. No abstract available.

6.

Can early response assessment guide neoadjuvant chemotherapy in early-stage breast cancer?

Esteva FJ, Hortobagyi GN.

J Natl Cancer Inst. 2008 Apr 16;100(8):521-3. doi: 10.1093/jnci/djn098. Epub 2008 Apr 8. No abstract available.

7.

Re: International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy.

Köstler WJ, Brodowicz T, Zielinski CC; Central European Cooperative Oncology Group (CECOG).

J Natl Cancer Inst. 2010 Feb 3;102(3):207; author reply 207-8. doi: 10.1093/jnci/djp483. Epub 2010 Jan 6. No abstract available.

8.

Combination versus sequential single-agent therapy in metastatic breast cancer.

Miles D, von Minckwitz G, Seidman AD.

Oncologist. 2002;7 Suppl 6:13-9. Review. Erratum in: Oncologist. 2003;8(1):127.

9.

Capecitabine and vinorelbine in metastatic breast cancer.

Chan A, Verrill M.

Eur J Cancer. 2009 Sep;45(13):2253-65. doi: 10.1016/j.ejca.2009.04.031. Epub 2009 May 20. Review.

PMID:
19464166
10.

Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review.

Oostendorp LJ, Stalmeier PF, Donders AR, van der Graaf WT, Ottevanger PB.

Lancet Oncol. 2011 Oct;12(11):1053-61. doi: 10.1016/S1470-2045(11)70045-6. Epub 2011 May 27. Review.

PMID:
21621462
11.

The evolving role of capecitabine in breast cancer.

O'Shaughnessy JA.

Clin Breast Cancer. 2003 Apr;4 Suppl 1:S20-5. Review.

PMID:
12756075
12.

Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series.

Ardavanis A, Tryfonopoulos D, Orfanos G, Karamouzis M, Scorilas A, Alexopoulos A, Rigatos G.

Onkologie. 2005 Nov;28(11):558-64.

PMID:
16249641
13.

The role of capecitabine in first-line treatment for patients with metastatic breast cancer.

Gelmon K, Chan A, Harbeck N.

Oncologist. 2006;11 Suppl 1:42-51. Review.

14.

Lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single institution experience.

Crivellari D, Spazzapan S, Lombardi D, Militello L, Torrisi E, Russo AE, Sorio R, Talamini R, Miolo G, Carli P, Veronesi A.

Tumori. 2012 Jan-Feb;98(1):33-8. doi: 10.1700/1053.11497.

PMID:
22495699
15.

Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer.

Huang H, Jiang Z, Wang T, Zhang S, Bian L, Cao Y, Wu S, Song S.

Anticancer Drugs. 2012 Aug;23(7):718-23. doi: 10.1097/CAD.0b013e328351802e.

PMID:
22739713
16.

Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial.

Miles D, Vukelja S, Moiseyenko V, Cervantes G, Mauriac L, Van Hazel G, Liu WY, Ayoub JP, O'Shaughnessy JA.

Clin Breast Cancer. 2004 Oct;5(4):273-8.

PMID:
15507172
17.

Prolonged disease control in a patient with anthracycline- and taxane-resistant breast cancer.

Castaneda CA, Gómez HL.

Clin Breast Cancer. 2009 Nov;9(4):E1-3. doi: 10.3816/CBC.2009.n.046.

PMID:
19933071
18.

Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study.

Huober J, von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm DM, Belau A, Khandan F, Hauschild M, Thomssen C, Högel B, Darb-Esfahani S, Mehta K, Loibl S.

Breast Cancer Res Treat. 2010 Nov;124(1):133-40. doi: 10.1007/s10549-010-1103-9. Epub 2010 Aug 10.

PMID:
20697801
19.

Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.

von Minckwitz G, Kümmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Huober J, Costa SD, Jackisch C, Loibl S, Mehta K, Kaufmann M; German Breast Group.

J Natl Cancer Inst. 2008 Apr 16;100(8):542-51. doi: 10.1093/jnci/djn085. Epub 2008 Apr 8.

20.

Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda) for locally advanced and/or metastatic breast cancer.

Jones L, Hawkins N, Westwood M, Wright K, Richardson G, Riemsma R.

Health Technol Assess. 2004 Feb;8(5):iii, xiii-xvi, 1-143. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk